Oxford, UK - 13 October 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that John Dawson has been appointed as permanent Chief Executive Officer with immediate effect, having served as Acting Chief Executive Officer since 29 August 2008.
